The results of the PRAIRI study were presented today at EULAR 2016 in London. These early findings suggest that individuals "at-risk" to develop rheumatoid arthritis (RA) may benefit from a short course of intravenously rituximab therapy.
JAMA has reported the results of an 18-year National Inpatient Sample, a database of US non-federal hospitalizations.
Desiree van der Heidje, MD, PhD presented the results of a 16-week, phase II, dose-ranging study of tofacitinib (TOFA) in patients with active ankylosing spondylitis.
The GiACTA study has published its top line results demonstrating the efficacy of adding tocilizumab (TCZ) to steroid-tapered therapy in patients with giant cell arteritis (GCA).
Methotrexate , a cornerstone drug used to treat rheumatoid arthritis, has led to 90 hospitalizations and 7 deaths according to a recent report from the Medical Journal of Australia.
The damaging potential of many inflammatory disorders is magnified by well-known associated comorbid conditions. This is particularly true in lupus, rheumatoid arthritis and psoriatic disease.
In April and May 2016, RheumNow sent 82 tweets regarding news, research and teaching points that strongly impacted the rheumatology community and resulted in a reach of 203,500 impressions, with 136 mentions, and over 6378 visits to RheumNow.com. Here are the top tweets from April and May.
This week's highlights from RheumNow.com include:
The NY Times reports that millions of Americans with osteoporosis are driven to stop or not take bisphosphonate therapies over the fear of exceedingly rare side effects - osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF).
Tenosynovitis may represent a preclinical phase of rheumatoid arthritis (RA).
Gastrointestinal perforations (GIP) are not historically believed to be a common or uncommon complication. Hence, when this was noted in the tocilizumab (TCZ) and tofacitinib (TOFA) developmental trials, it was a curious if not perplexing finding.
Pain management in the U.S. is at a vexing crossroad. The news tells us that narcotics are increasingly being restricted for their dangerous side effects and inappropriate use.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
